Ei tuo lääkehoitokaan ihan halpaa ole. Tuosta NBC:n uutisesta lainattua:
When the two groups were compared using standard cognitive tests, the researchers found the patients receiving TMS therapy had a 44% slower rate of symptoms worsening.
To put that in perspective, two of the newer medications, lecanemab and donanemab, have been shown to moderately slow a decline in memory and thinking abilities — by 27.1% and 22.3%, respectively. The treatments are monoclonal antibody infusions, given every two or four weeks and are costly — $26,500 to $32,000 per patient per year. Both are associated with an increased risk of brain swelling and microhemorrhages.